ReviewPaediatric drugs2020
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents.
Review in Paediatric drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 83 citations in OpenAlex.
- Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.Frontiers in immunology · 2026Review
- Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection.Frontiers in allergy · 2026Review
- Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study.Annals of medicine · 2025Article
- Real-World Assessment of Dupilumab in Chinese Atopic Dermatitis Patients: Efficacy, Safety, and Impact of Comorbidities.Journal of asthma and allergy · 2025Article
- An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma.Children (Basel, Switzerland) · 2024Review
- IgE and anaphylaxis specific to the carbohydrate alpha-gal depend on IL-4.The Journal of allergy and clinical immunology · 2024Article
- A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.Drug design, development and therapy · 2024Review
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- A Practical Update on Pediatric Eosinophilic Esophagitis.Children (Basel, Switzerland) · 2023Review
- Proteomic characterization of atopic dermatitis blood from infancy to adulthood.Journal of the American Academy of Dermatology · 2023Observational
- Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.Expert review of clinical pharmacology · 2023Review
- Eosinophilic Gastrointestinal Diseases in Inborn Errors of Immunity.Journal of clinical medicine · 2023Review
- OR2AT4 and OR1A2 counterregulate molecular pathophysiological processes of steroid-resistant inflammatory lung diseases in human alveolar macrophages.Molecular medicine (Cambridge, Mass.) · 2022Article
- Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome.JAAD case reports · 2022Article
- Biologic Therapies in Pediatric Asthma.Journal of personalized medicine · 2022Review
- Eosinophilic esophagitis an update in children.Acta bio-medica : Atenei Parmensis · 2022Article
- Survey on Use of Local and Systemic Corticosteroids in the Management of Chronic Rhinosinusitis with Nasal Polyps: Identification of Unmet Clinical Needs.Journal of personalized medicine · 2022Article
- Probiotics Function in Preventing Atopic Dermatitis in Children.International journal of molecular sciences · 2022Review
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL-4R signaling induced by both IL-4 and IL-13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.